Bullish & Foolish
Full CVKD fundamentals All 466 on the Survival Watch

CVKDCADRENAL THERAPEUTICS, INC.

Is Cadrenal Therapeutics struggling financially?

Yes, by its own account. Cadrenal Therapeutics told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

10/100

Critical

Sector
Biotech/Pharma
Market cap
$5.7M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$2.4M

÷

Cash burned over the last 12 months

$12.6M

What Cadrenal Therapeutics told the SEC

…at all. As a result, there is uncertainty as to the Company’s ability to meet its current operating and capital expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued. If the Company is unable to raise additional funding to meet its working capital needs in the…

CADRENAL THERAPEUTICS, INC., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 39.9% share-count increase The company issued stock. Each share now owns 28.5% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt